Funded Grants

By the time a person receives a diagnosis of Alzheimer’s disease (AD) dementia, brain atrophy is such that memory impairments are irreversible.

Neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease profoundly affect aspects of cognition including memory

Brain-based disorders such as epilepsy, stroke, acquired brain injury, and Parkinson’s Disease impact tens of thousands of Canadians each year.

The recent breakthrough technology of single-cell genomics has vastly improved our capacity to understand how the trillions of cells in our body develop and work together to make us human.

In 2017, Canada saw 89,500 new strokes in people aged 20 and older and counted 878,500 people living with stroke.

Mood disorders such as depression and bipolar disorder affect over 350 million people around the world.

Patients with neurological disease are understandably frustrated by the lack of meaningful pharmacological treatments for even comparatively common pathologies such as Parkinson’s Disease.

Injuries and diseases of the nervous system have devastating effects.

The demonstration that mature somatic cells can be converted to new, heterologous cell types, now termed “cellular reprogramming”, led to the 2012 Nobel Prize in Physiology or Medicine, and sparked an explosion of studies investigating the therapeutic potential of such an approach.